IL-33 restricts tumor growth and inhibits pulmonary metastasis in melanoma-bearing mice through eosinophils

Valeria Lucarini, Giovanna Ziccheddu, Iole Macchia, Valentina La Sorsa, Francesca Peschiaroli, Carla Buccione, Antonella Sistigu, Massimo Sanchez, Sara Andreone, Maria Teresa D'Urso, Massimo Spada, Daniele Macchia, Claudia Afferni, Fabrizio Mattei, Giovanna Schiavoni

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

The alarmin IL-33 is an IL-1 family member that stimulates pleiotropic immune reactions depending on the target tissue and microenvironmental factors. In this study, we have investigated the role of IL-33/ST2 axis in antitumor response to melanoma. Injection of IL-33 in mice-bearing subcutaneous B16.F10 melanoma resulted in significant tumor growth delay. This effect was associated with intratumoral accumulation of CD8+ T cells and eosinophils, decrease of immunosuppressive myeloid cells, and a mixed Th1/Th2 cytokine expression pattern with local and systemic activation of CD8+ T and NK cells. Moreover, intranasal administration of IL-33 determined ST2-dependent eosinophil recruitment in the lung that prevented the onset of pulmonary metastasis after intravenous injection of melanoma cells. Accordingly, ST2-deficient mice developed pulmonary metastasis at higher extent than wild-type counterparts, associated with lower eosinophil frequencies in the lung. Of note, depletion of eosinophils by in vivo treatment with anti-Siglec-F antibody abolished the ability of IL-33 to both restrict primary tumor growth and metastasis formation. Finally, we show that IL-33 is able to activate eosinophils resulting in efficient killing of target melanoma cells, suggesting a direct antitumor activity of eosinophils following IL-33 treatment. Our results advocate for an eosinophil-mediated antitumoral function of IL-33 against melanoma, thus opening perspectives for novel cancer immunotherapy strategies.

Original languageEnglish
Article numbere1317420
JournalOncoImmunology
Volume6
Issue number6
DOIs
Publication statusPublished - Jun 3 2017

Fingerprint

Eosinophils
Melanoma
Neoplasm Metastasis
Lung
Growth
Neoplasms
Sialic Acid Binding Immunoglobulin-like Lectins
T-Lymphocytes
Intranasal Administration
Aptitude
Interleukin-33
Thromboplastin
Myeloid Cells
Immunosuppressive Agents
Interleukin-1
Intravenous Injections
Natural Killer Cells
Immunotherapy
Cytokines
Injections

Keywords

  • Eosinophils
  • interleukin (IL)-33
  • melanoma
  • mouse models
  • pulmonary metastasis

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Oncology

Cite this

IL-33 restricts tumor growth and inhibits pulmonary metastasis in melanoma-bearing mice through eosinophils. / Lucarini, Valeria; Ziccheddu, Giovanna; Macchia, Iole; La Sorsa, Valentina; Peschiaroli, Francesca; Buccione, Carla; Sistigu, Antonella; Sanchez, Massimo; Andreone, Sara; D'Urso, Maria Teresa; Spada, Massimo; Macchia, Daniele; Afferni, Claudia; Mattei, Fabrizio; Schiavoni, Giovanna.

In: OncoImmunology, Vol. 6, No. 6, e1317420, 03.06.2017.

Research output: Contribution to journalArticle

Lucarini, Valeria ; Ziccheddu, Giovanna ; Macchia, Iole ; La Sorsa, Valentina ; Peschiaroli, Francesca ; Buccione, Carla ; Sistigu, Antonella ; Sanchez, Massimo ; Andreone, Sara ; D'Urso, Maria Teresa ; Spada, Massimo ; Macchia, Daniele ; Afferni, Claudia ; Mattei, Fabrizio ; Schiavoni, Giovanna. / IL-33 restricts tumor growth and inhibits pulmonary metastasis in melanoma-bearing mice through eosinophils. In: OncoImmunology. 2017 ; Vol. 6, No. 6.
@article{83bf95a0696848d5b78a60496e621021,
title = "IL-33 restricts tumor growth and inhibits pulmonary metastasis in melanoma-bearing mice through eosinophils",
abstract = "The alarmin IL-33 is an IL-1 family member that stimulates pleiotropic immune reactions depending on the target tissue and microenvironmental factors. In this study, we have investigated the role of IL-33/ST2 axis in antitumor response to melanoma. Injection of IL-33 in mice-bearing subcutaneous B16.F10 melanoma resulted in significant tumor growth delay. This effect was associated with intratumoral accumulation of CD8+ T cells and eosinophils, decrease of immunosuppressive myeloid cells, and a mixed Th1/Th2 cytokine expression pattern with local and systemic activation of CD8+ T and NK cells. Moreover, intranasal administration of IL-33 determined ST2-dependent eosinophil recruitment in the lung that prevented the onset of pulmonary metastasis after intravenous injection of melanoma cells. Accordingly, ST2-deficient mice developed pulmonary metastasis at higher extent than wild-type counterparts, associated with lower eosinophil frequencies in the lung. Of note, depletion of eosinophils by in vivo treatment with anti-Siglec-F antibody abolished the ability of IL-33 to both restrict primary tumor growth and metastasis formation. Finally, we show that IL-33 is able to activate eosinophils resulting in efficient killing of target melanoma cells, suggesting a direct antitumor activity of eosinophils following IL-33 treatment. Our results advocate for an eosinophil-mediated antitumoral function of IL-33 against melanoma, thus opening perspectives for novel cancer immunotherapy strategies.",
keywords = "Eosinophils, interleukin (IL)-33, melanoma, mouse models, pulmonary metastasis",
author = "Valeria Lucarini and Giovanna Ziccheddu and Iole Macchia and {La Sorsa}, Valentina and Francesca Peschiaroli and Carla Buccione and Antonella Sistigu and Massimo Sanchez and Sara Andreone and D'Urso, {Maria Teresa} and Massimo Spada and Daniele Macchia and Claudia Afferni and Fabrizio Mattei and Giovanna Schiavoni",
year = "2017",
month = "6",
day = "3",
doi = "10.1080/2162402X.2017.1317420",
language = "English",
volume = "6",
journal = "OncoImmunology",
issn = "2162-4011",
publisher = "Taylor and Francis Inc.",
number = "6",

}

TY - JOUR

T1 - IL-33 restricts tumor growth and inhibits pulmonary metastasis in melanoma-bearing mice through eosinophils

AU - Lucarini, Valeria

AU - Ziccheddu, Giovanna

AU - Macchia, Iole

AU - La Sorsa, Valentina

AU - Peschiaroli, Francesca

AU - Buccione, Carla

AU - Sistigu, Antonella

AU - Sanchez, Massimo

AU - Andreone, Sara

AU - D'Urso, Maria Teresa

AU - Spada, Massimo

AU - Macchia, Daniele

AU - Afferni, Claudia

AU - Mattei, Fabrizio

AU - Schiavoni, Giovanna

PY - 2017/6/3

Y1 - 2017/6/3

N2 - The alarmin IL-33 is an IL-1 family member that stimulates pleiotropic immune reactions depending on the target tissue and microenvironmental factors. In this study, we have investigated the role of IL-33/ST2 axis in antitumor response to melanoma. Injection of IL-33 in mice-bearing subcutaneous B16.F10 melanoma resulted in significant tumor growth delay. This effect was associated with intratumoral accumulation of CD8+ T cells and eosinophils, decrease of immunosuppressive myeloid cells, and a mixed Th1/Th2 cytokine expression pattern with local and systemic activation of CD8+ T and NK cells. Moreover, intranasal administration of IL-33 determined ST2-dependent eosinophil recruitment in the lung that prevented the onset of pulmonary metastasis after intravenous injection of melanoma cells. Accordingly, ST2-deficient mice developed pulmonary metastasis at higher extent than wild-type counterparts, associated with lower eosinophil frequencies in the lung. Of note, depletion of eosinophils by in vivo treatment with anti-Siglec-F antibody abolished the ability of IL-33 to both restrict primary tumor growth and metastasis formation. Finally, we show that IL-33 is able to activate eosinophils resulting in efficient killing of target melanoma cells, suggesting a direct antitumor activity of eosinophils following IL-33 treatment. Our results advocate for an eosinophil-mediated antitumoral function of IL-33 against melanoma, thus opening perspectives for novel cancer immunotherapy strategies.

AB - The alarmin IL-33 is an IL-1 family member that stimulates pleiotropic immune reactions depending on the target tissue and microenvironmental factors. In this study, we have investigated the role of IL-33/ST2 axis in antitumor response to melanoma. Injection of IL-33 in mice-bearing subcutaneous B16.F10 melanoma resulted in significant tumor growth delay. This effect was associated with intratumoral accumulation of CD8+ T cells and eosinophils, decrease of immunosuppressive myeloid cells, and a mixed Th1/Th2 cytokine expression pattern with local and systemic activation of CD8+ T and NK cells. Moreover, intranasal administration of IL-33 determined ST2-dependent eosinophil recruitment in the lung that prevented the onset of pulmonary metastasis after intravenous injection of melanoma cells. Accordingly, ST2-deficient mice developed pulmonary metastasis at higher extent than wild-type counterparts, associated with lower eosinophil frequencies in the lung. Of note, depletion of eosinophils by in vivo treatment with anti-Siglec-F antibody abolished the ability of IL-33 to both restrict primary tumor growth and metastasis formation. Finally, we show that IL-33 is able to activate eosinophils resulting in efficient killing of target melanoma cells, suggesting a direct antitumor activity of eosinophils following IL-33 treatment. Our results advocate for an eosinophil-mediated antitumoral function of IL-33 against melanoma, thus opening perspectives for novel cancer immunotherapy strategies.

KW - Eosinophils

KW - interleukin (IL)-33

KW - melanoma

KW - mouse models

KW - pulmonary metastasis

UR - http://www.scopus.com/inward/record.url?scp=85019598855&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85019598855&partnerID=8YFLogxK

U2 - 10.1080/2162402X.2017.1317420

DO - 10.1080/2162402X.2017.1317420

M3 - Article

AN - SCOPUS:85019598855

VL - 6

JO - OncoImmunology

JF - OncoImmunology

SN - 2162-4011

IS - 6

M1 - e1317420

ER -